High purity factor VIII concentrates for the treatment of HIV-positive patients with haemophilia.
Some factor VIII concentrates cause downregulation of the immune system in HIV-positive haemophilia patients. This effect appears to be related to the purity of the concentrate, but not to its method of preparation. The optimum purity for preventing downregulation is not known at present.
D000293:Adolescent; D000328:Adult; D018791:CD4 Lymphocyte Count; D002852:Chromatography, Ion Exchange; D015536:Down-Regulation; D005169:Factor VIII / Q000009:adverse effects / Q000302:isolation & purification*; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000276:immunology; D006467:Hemophilia A / Q000150:complications*; D006801:Humans; D008875:Middle Aged
D005169:Factor VIII